No ‘easy targets’ for Omass, which adds $95M series B for small-molecule work

Published

April 29, 2022

No ‘easy targets’ for Omass, which adds $95M series B for small-molecule work

OMass Therapeutics Ltd. has raised £75.5 million (US$94.6 million) in a series B round, as it continues to advance five small-molecule programs against previously intractable membrane-bound targets to the clinic…

MORERelated News
Ros Deegan: Always up for a new challenge: How Ros carved out a path to lead her own company
Always up for a new challenge, Ros describes the many twists and turns her career has taken over the years....
Lab crunch: British science has nowhere to go
OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm...
Native mass spectrometry: Drug discovery’s new kid on the block
Current drug discovery methods have limited success against certain drug targets and better approaches are needed. Professor Dame Carol Robinson’s...